BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Purchased by Principal Financial Group Inc.

Principal Financial Group Inc. boosted its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 1,058.1% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 411,414 shares of the biotechnology company's stock after purchasing an additional 375,890 shares during the quarter. Principal Financial Group Inc. owned approximately 0.20% of BioCryst Pharmaceuticals worth $3,127,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of the company. Exome Asset Management LLC acquired a new position in shares of BioCryst Pharmaceuticals during the third quarter valued at about $1,493,000. Franklin Resources Inc. grew its stake in BioCryst Pharmaceuticals by 177.8% during the 3rd quarter. Franklin Resources Inc. now owns 263,748 shares of the biotechnology company's stock valued at $1,968,000 after purchasing an additional 168,790 shares during the last quarter. Sanctuary Advisors LLC increased its holdings in shares of BioCryst Pharmaceuticals by 78.3% in the third quarter. Sanctuary Advisors LLC now owns 47,389 shares of the biotechnology company's stock valued at $360,000 after purchasing an additional 20,818 shares during the period. SkyView Investment Advisors LLC raised its stake in shares of BioCryst Pharmaceuticals by 30.0% in the third quarter. SkyView Investment Advisors LLC now owns 13,000 shares of the biotechnology company's stock worth $99,000 after purchasing an additional 3,000 shares during the last quarter. Finally, Geode Capital Management LLC lifted its holdings in shares of BioCryst Pharmaceuticals by 2.7% during the third quarter. Geode Capital Management LLC now owns 4,837,985 shares of the biotechnology company's stock worth $36,776,000 after purchasing an additional 127,708 shares during the period. 85.88% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

BCRX has been the topic of several research reports. Barclays increased their price target on shares of BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the stock an "equal weight" rating in a report on Tuesday, November 5th. Royal Bank of Canada reiterated an "outperform" rating and issued a $10.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday, November 5th. Finally, Needham & Company LLC restated a "buy" rating and set a $14.00 target price on shares of BioCryst Pharmaceuticals in a research report on Tuesday, November 5th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat, BioCryst Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average price target of $15.60.

BioCryst Pharmaceuticals Stock Down 1.7 %

Shares of NASDAQ BCRX traded down $0.13 during midday trading on Friday, reaching $7.70. 1,267,113 shares of the stock were exchanged, compared to its average volume of 2,186,907. The firm has a market cap of $1.59 billion, a price-to-earnings ratio of -12.62 and a beta of 1.76. The firm has a 50-day simple moving average of $7.61 and a two-hundred day simple moving average of $7.52. BioCryst Pharmaceuticals, Inc. has a twelve month low of $4.03 and a twelve month high of $8.88.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last posted its earnings results on Monday, November 4th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.07). The firm had revenue of $117.10 million for the quarter, compared to analysts' expectations of $113.99 million. During the same period in the previous year, the company earned ($0.19) earnings per share. The company's revenue was up 35.1% compared to the same quarter last year. Research analysts expect that BioCryst Pharmaceuticals, Inc. will post -0.38 EPS for the current fiscal year.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.